Sign In
Buy EYEN
$7.56
+0 (+0%)
At Close: Jan 16, 2026
Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
08:30am, Monday, 10'th May 2021
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, to
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2020 Results - Earnings Call Transcript
10:50pm, Thursday, 25'th Mar 2021
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2020 Results - Earnings Call Transcript
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
04:05pm, Thursday, 25'th Mar 2021
Announces MydCombi expected PDUFA date of October 28, 2021
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
07:30am, Tuesday, 23'rd Mar 2021
NEW YORK & CHICAGO--(BUSINESS WIRE)-- #MydCombi--Eyenovia has tapped EVERSANA as exclusive distributor of its MydCombi product for pupil dilation in the U.S., pending the product's FDA approval.
NEW YORK--(BUSINESS WIRE)-- #Optejet--Eyenovia's MAP™ fixed-combination pharmaceutical for pupil dilation has been shown to be safe, effective and superior in comparative study.
EYEN Stock Price Increases Over 15% Pre-Market: Why It Happened
08:09am, Tuesday, 02'nd Mar 2021
The stock price of Eyenovia, Inc. (Nasdaq: EYEN) has increased by over 15% pre-market. This is why it happened.
Eyenovia Announces FDA Acceptance of the MydCombi NDA
07:30am, Tuesday, 02'nd Mar 2021
NEW YORK--(BUSINESS WIRE)-- #mydriasis--FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
08:00am, Tuesday, 16'th Feb 2021
The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET The webinar, “Presbyopia in Focus: Unlo
Circling Back On Eyenovia
10:24am, Sunday, 03'rd Jan 2021
Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a marketing ap
NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
10:01pm, Tuesday, 10'th Nov 2020
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
08:00am, Thursday, 05'th Nov 2020
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting
12:00am, Monday, 05'th Oct 2020
Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020
Eyenovia, Inc. Prices Public Offering of Common Stock
01:10pm, Wednesday, 19'th Aug 2020
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, t
